← Leaderboards
Ofer Sadan
Emory University
$1,646,292
Attributed
$1,646,292
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $497.4K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,646,292 · 1
By mechanism
R01$1,646,292 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Xiao Hu$15,500,109
- Paul M Vespa$9,060,810
- William Robert Taylor$39,404,588
- Raymond J Dingledine$29,610,268
- Andrew John Butler$607,506
Others in their field
Other Rising Stars on “Affinity”
- Jason Dickens · Duke University$12,259,409
- Jeff T Hutchins · Inhalon Biopharma, Inc.$8,734,904
- Joseph Fraser Glickman · Hackensack University Medical Center$8,363,749
- Mark Sorenson · Nirsum Laboratories, Inc.$4,866,388
- Michael P Weiner · Abbratech, Inc.$4,404,422
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$3,945,669
Research focus
AffinityAftercareBilateralBiological MarkersBiomarker DevelopmentBloodBlood FlowBlood Pressure ReductionBlood VesselsBrainBrain InjuriesCalcium Channel BlockersCerebral IschemiaCerebrospinal FluidCerebrovascularCerebrovascular CirculationCerebrovascular SpasmCerebrovascular SystemCerebrumCohortConstrictionDeoxyhemoglobinDetectionAdopted
Grant awards (4)
Development of Biomarkers to Optimize Intrathecal Nicardipine Treatment for Cerebral Vasospasm and Delayed Cerebral Ischemia after Subarachnoid Hemorrhage$386,840
R01 · FY2025 · NS · contact PI
Development of biomarkers to optimize intrathecal nicardipine treatment for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage$375,235
R01 · FY2024 · NS · contact PI
Development of biomarkers to optimize intrathecal nicardipine treatment for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage$386,840
R01 · FY2023 · NS · contact PI
Development of biomarkers to optimize intrathecal nicardipine treatment for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage$497,377
R01 · FY2022 · NS · contact PI